http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Ken Ueno (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
A PTAT Voltage Source consisting of Subthreshold MOSFETs for Temperature Sensor LSIs
Ken Ueno,Tetsuya Asai,Yoshihito Amemiya 대한전자공학회 2009 ITC-CSCC :International Technical Conference on Ci Vol.2009 No.7
An ultra-low power temperature sensor circuit based on a subthreshold MOSFET was proposed. The sensor consists of a modified β-multiplier self biasing circuit that uses a switched capacitor resistor instead of ordinary resistors. The circuit is operated in the subthreshold region, and it generates a proportional to absolute temperature (PTAT) voltage. Simulation with SPICE demonstrated that the circuit can be used as a smart temperature sensor with ultra-low power consumption of 3.5 ㎼ or less. The accuracy of the sensor output was within ±1.5℃.
-
The trial manufacture of aid to assist to play bowling for people with serious disabilities
Tadahiro Ueno,Ken Maruyama,Kyouji Kojima,Tomoko Kitagawa 한국재활복지공학회 2011 한국재활복지공학회 학술대회논문집 Vol.2011 No.11
This paper describes the process of developing the aid which assists to play bowling for people with serious disabilities. The aid is constructed slopes for bowling (which are normally on the market), powered motors, controller and switches for operation. Users who have never played bowling until this time have serious disabilities that are paralysis of the limbs for cerebral palsy, muscle dystrophy and so on. User"s impressions are almost good. But it is necessary to make the sequence of operation easy for people with more various disabilities.
-
High-resistance resistors consisting of subthreshold-operated CMOS circuits
Shin’ichi Asai,Ken Ueno,Tetsuya Asai,Yoshihito Amemiya 대한전자공학회 2009 ITC-CSCC :International Technical Conference on Ci Vol.2009 No.7
We propose a CMOS circuit that can be used as an equivalent of resistors. This circuit uses a differential pair consisting of diode-connected MOSFETs and operates as a high-resistance resistor when driven in the subthreshold region. Its resistance can be controlled in a range of 1-1000 ㏁ by adjusting the driving current for the circuit. The results of the fabrication and measurement of the circuit are described.
-
The Impact of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer
( Manabu Kawai ),( Seiko Hirono ),( Ken-ichi Okada ),( Motoki Miyazawa ),( Yuji Kitahata ),( Ryohei Kobayashi ),( Masaki Ueno ),( Shinya Hayami ),( Hiroki Yamaue ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Backgrounds: According to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines, pancre atic ductal adenocarcinoma (PDAC) can be classified as resectable, borderline resectable, or unresectable. Although borderline resectable PDAC (BRPC) may technically be resectable, it has particularly high risks of margin-positive resection and postoperative recurrence. Therefore, preoperative treatment is recommended for BRPC patients in both the NCCN Guidelines and an expert consensus statement. However, the establishment of the most appropriate neoadjuvant therapy is needed by further studies. The aim of these studies is to evaluate the impact of neoadjuvant chemotherapy for BRPC and confirm the safety and efficacy of two regimens of neoadjuvant therapy for BRPC. Our Clinical Trials: First, we evaluated the impact of neoadjuvant chemotherapy for BRPC. 143 BRPC-A patients un dergoing pancreatectomy were reviewed from among 330 pancreatic cancer patients, including 111 potentially resectable pancreatic cancer patients and 76 BRPC with portal vein involvement patients. We compared the clinico pathological factors of 40 BRPC-A patients treated with neoadjuvant treatment followed by surgery and those of 103 BRPC-A patients treated with upfront surgery. The R0 rate and progression-free survival of BRPC-A patients who received neoadjuvant therapy and subsequent surgical resection were significantly better compared to those who re ceived upfront surgery (R0: P = 0.041; progression-free survival: P = 0.033), but overall survival was not significantly different. Neoadjuvant treatment followed by surgery might provide clinical benefits for BRPC-A patients; however, the establishment of the most appropriate neoadjuvant treatment is needed by further studies. To evaluate appro priate neoadjuvant treatment, two prospective pilot trials were conducted as follows; modified FOLFIRINOX (without bolus 5-FU and LV, also decreased the dose of irinotecan; FIRINOX) and nab-paclitaxel plus gemcitabine therapy. Modified FOLFIRINOX was given to the first five patients in the 4-cycle group of the regimen and next five patients in the 8-cycle group. The primary end point was the toxicity of the therapy and one of the secondary end points were the optimal duration. The overall rate of grade 3 and 4 events was 80 %: 3 patients (60%) in the four-cycle group and five patients (100%) in the eight-cycle group had grade 3 or 4 adverse events. There was no incidence of seri ous adverse effect such as febrile neutropenia, sepsis, liver abscess or uncontrollable diarrhea. There was no clinically relevant morbidity presented in patients who underwent surgery. R0 rates by intention to treat were 60.0% in the four-cycle group and 40 % in the eight-cycle group (P = 0.999). The histopathologic treatment effect based on the Evans grade revealed grade I (n = 1), IIa (n = 3) in the four-cycle group and grade I (n = 2), IIa (n = 1) in the eight-cy cle group. Nab-paclitaxel plus gemcitabine therapy: the primary endpoint was the toxicity, and secondary endpoints were the resection rate, the R0 resection rate. The overall rate of any grade and grade 3-4 events were 100% and 90%. The majority of these adverse events represented expected neutropenia. The resection and R0 resection rates were 80% and 70%, respectively. Conclusion: FIRINOX therapy was feasible and safe for strictly selected patients with BRPC. On the other hand, nab-pa clitaxel plus gemcitabine therapy was safe and feasible without strict selection of patients with BRPC. A multicenter phase II study is in progress to investigate the efficacy of neoadjuvant nab-paclitaxel plus gemcitabine therapy on overall survival (UMIN000024154).
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
